PURPOSE: The risk for death in patients with retinoblastoma is increased in those who present with metastatic disease, and the role of intensive chemotherapy and autologous hematopoietic stem cell rescue in these patients remains unclear. DESIGN: Nonrandomized interventional case series. PARTICIPANTS: Four consecutive patients with metastatic retinoblastoma. METHODS: We treated four patients with retinoblastoma metastatic to the bone and bone marrow with intensive chemotherapy, consolidation with megatherapy, and autologous hematopoietic stem cell rescue. Chemotherapy included courses of carboplatin and etoposide alternating with cyclophosphamide, etoposide, and either carboplatin or cisplatin. Radiation therapy was delivered to areas of bone metastases. MAIN OUTCOME MEASURES: Patient survival. RESULTS: All patients completed and responded to the scheduled therapy; complete response of the bone marrow disease was documented after two courses of chemotherapy in all cases. Two patients are long-term survivors. CONCLUSIONS: The treatment described has been successful in obtaining disease-free survival in patients with metastatic retinoblastoma.
PURPOSE: The risk for death in patients with retinoblastoma is increased in those who present with metastatic disease, and the role of intensive chemotherapy and autologous hematopoietic stem cell rescue in these patients remains unclear. DESIGN: Nonrandomized interventional case series. PARTICIPANTS: Four consecutive patients with metastatic retinoblastoma. METHODS: We treated four patients with retinoblastoma metastatic to the bone and bone marrow with intensive chemotherapy, consolidation with megatherapy, and autologous hematopoietic stem cell rescue. Chemotherapy included courses of carboplatin and etoposide alternating with cyclophosphamide, etoposide, and either carboplatin or cisplatin. Radiation therapy was delivered to areas of bone metastases. MAIN OUTCOME MEASURES: Patient survival. RESULTS: All patients completed and responded to the scheduled therapy; complete response of the bone marrow disease was documented after two courses of chemotherapy in all cases. Two patients are long-term survivors. CONCLUSIONS: The treatment described has been successful in obtaining disease-free survival in patients with metastatic retinoblastoma.
Authors: Carlos A Leal-Leal; Roberto Rivera-Luna; Martha Flores-Rojo; Juan C Juárez-Echenique; Juan C Ordaz; Jorge Amador-Zarco Journal: Clin Transl Oncol Date: 2006-01 Impact factor: 3.405
Authors: Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2013-02-15 Impact factor: 3.167
Authors: Sofia Theodoropoulou; Paraskevi E Kolovou; Yuki Morizane; Maki Kayama; Fotini Nicolaou; Joan W Miller; Evangelos Gragoudas; Bruce R Ksander; Demetrios G Vavvas Journal: FASEB J Date: 2010-04-06 Impact factor: 5.191
Authors: Wai Kit Chu; Ka Sin Law; Sun On Chan; Jason Cheuk Sing Yam; Li Jia Chen; Hao Zhang; Herman S Cheung; Norman L Block; Andrew V Schally; Chi Pui Pang Journal: Proc Natl Acad Sci U S A Date: 2016-11-23 Impact factor: 11.205
Authors: Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson Journal: Curr Treat Options Neurol Date: 2007-07 Impact factor: 3.598
Authors: Katarzyna Brodowska; Ahmad Al-Moujahed; Anna Marmalidou; Melissa Meyer Zu Horste; Joanna Cichy; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas Journal: Exp Eye Res Date: 2014-05-15 Impact factor: 3.467
Authors: Chie-Schin Shih; Nikia Laurie; Jeremy Holzmacher; Yunyu Spence; Amit C Nathwani; Andrew M Davidoff; Michael A Dyer Journal: Neuromolecular Med Date: 2009-03-22 Impact factor: 3.843